28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
The central nervous system is emerging as an important target for adverse health effects of air pollution, where it may contribute to neurodevelopmental and neurodegenerative disorders. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Air pollution is an important cause of non-communicable diseases globally with particulate matter (PM) as one of the main air pollutants. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
PM2.5 particles in air pollution have been widely considered associated with respiratory and cardiovascular diseases. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In this article the neurotoxic disorders appearing in patients exposed to organophosphorus pesticides and known mechanisms involved are reviewed. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Organophosphorus pesticides (OPs) are widely used for controlling pests worldwide. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The purpose of this review is to describe recent clinical and epidemiological studies examining the adverse effects of urban air pollution on the central nervous system (CNS). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Exposure to ambient air pollution and noise is ubiquitous globally. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Traffic-related air pollution (TRAP) is associated with lower cognition and reduced white matter volume in older adults, specifically for particulate matter <2.5-μm diameter (PM 2.5 ). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Airborne particulate matter poses a serious threat to human health. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Millions of children and young adults are exposed to fine particulate matter (PM2.5) and ozone, associated with Alzheimer's disease (AD) risk. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Pesticides are widely-used chemicals commonly applied in agriculture for the protection of crops from pests. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
These innovations can be benchmarked on firm understanding of nutrigenomics and the personalized management of individuals at risk. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neurodegenerative disorders are typically sporadic in nature in addition to usually influenced through an extensive range of environmental factors, lifestyle, and genetic elements. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
There is growing evidence that air pollution is a risk factor for a number of neurodegenerative diseases, most notably Alzheimer's (AD) and Parkinson's (PD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Increasing evidence points to an association of airborne pollutant exposure with respiratory, cardiovascular, and neurological pathology. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Organophosphorus (OP) compounds have been known as the most widely used pesticides during the past half century and there have been a huge body of literature regarding their association with human chronic diseases. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Traffic-related air pollution particulate matter (TRAP-PM) is associated with increased risk of Alzheimer Disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Fewer than 5% of Alzheimer's disease (AD) cases are demonstrably directly inherited, indicating that environmental factors may be important in initiating and/or promoting the disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Bright light is a treatment of choice for seasonal affective disorder. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Melatonin is a hormone synthesized in the pineal gland from tryptophan. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The older patient population is growing rapidly around the world and in the USA. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep disturbance is common in patients with dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A clinically relevant sleep-wake disturbance is found in up to half the patients with dementia, and the sundowning agitation is a common cause of institutionalisation of demented geriatric patients. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep disorders appear to be frequent comorbidities in patients with frontotemporal dementia (FTD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The relationship of sleep apnea to age, sex, and Alzheimer's dementia was investigated in 45 elderly subjects and 10 young males, all nonobese, normotensive, nonsmoking, with no sleep complaints and no medical problems other than Alzheimer's disease. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →